Nexalis Therapeutics (ASX:NX1) Total Receivables: A$0.92 Mil (As of Dec. 2025)


What is Nexalis Therapeutics Total Receivables?

Nexalis Therapeutics ASX:NX1 Total Receivables is A$0.92 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Nexalis Therapeutics's Total Receivables for the quarter that ended in Dec. 2025 was A$0.92 Mil.

Nexalis Therapeutics Total Receivables Related Terms

Nexalis Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics Total Receivables Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.06 0.80 0.45 0.92

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.14 0.45 0.96 0.92

Nexalis Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$0.92 Mil mean?
Nexalis Therapeutics (ASX:NX1) has a Total Receivables of A$0.92 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Nexalis Therapeutics and its competitors.
Is Nexalis Therapeutics' Total Receivables too high?
Nexalis Therapeutics' current Total Receivables is A$0.92 Mil.
How does Nexalis Therapeutics' Total Receivables compare to VRTX and REGN?
Nexalis Therapeutics' Total Receivables of A$0.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current Total Receivables is A$0.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current Total Receivables of A$0.92 Mil. The current Total Receivables is A$0.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current Total Receivables is A$0.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.